Mizagliflozin

N/A

Report date: 2023/12/01 15:54:14
NME

Base Information

Drug NameMizagliflozin
Drug Alias NameKWA-0711GSK-1614235DSP-3235KGA-3235KGA +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 1 inhibitors
TargetsSodium/glucose cotransporter 1
Therapy Area/IndicationsPost-bariatric HypoglycemiaConstipationDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKissei Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVogenx Inc
Inactive CompaniesGlaxosmithkline PlcKissei Pharmaceutical Co Ltd
Active IndicationsPost-bariatric Hypoglycemia
Inactive IndicationsConstipationDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A